Action for Sustainable Derivatives’ Post

Research Partnership has the size, knowledge, experience and expert solutions to provide a greater breadth and depth of #qualitative insights. We can help you get a deeper understanding of the global market at scale, using frameworks to identify emerging opportunities and make informed decisions to drive your brands' success. Click to find out more: https://lnkd.in/e_F_vs3y #Pharma #MarketResearch #qualitativeresearch

Exploring Risks and Opportunities in The Pharma Industry 💊 Pharmaceutical companies face myriad challenges and opportunities in today's complex market. With factors like the aging population, financial constraints, healthcare personnel shortages, and demand for a high-skilled workforce shaping the landscape, the industry navigates a diverse array of obstacles and prospects. In this infographic, I've outlined the key risks and opportunities. Which do you believe will wield the greatest influence? 💬 #Pharma #Risks #Opportunities

Rising to the challenge. 🥼 The global impact of the Covid-19 pandemic emphasized the critical role of the pharmaceutical manufacturing industry in supporting resilient economies and communities. Following the pandemic numerous countries around the world committed to invest more in science, technology, and innovation. However, challenges persist for the sector including shoring up delicate supply chains, the need to decarbonise and keeping up with the pace of change.   Read insights from Business Unit Director of Pharma and Life Sciences for Consultancy, James Atkinson, as he explores the solutions to tackle these key pain points: https://lnkd.in/eCUsuYYw

Pharmaceutical companies often face criticism for prioritizing new drug launches in high-income countries, neglecting equitable healthcare in emerging markets and low- to middle-income countries (LMICs). Yet, these markets offer untapped growth opportunities and a chance to promote global healthcare equity. Join our webinar with our experts Marc Matar and Joshua Siow to uncover the next chapter of pharma growth and gain insights into equitable market access in emerging markets and LMICs. Register now to secure your spot: https://lnkd.in/eNCQpSX2 #PharmaGrowth #EquitableAccess #SimonKucher #EmergingMarkets #BetterMarketAccess #Healthcare

The pharmaceutical industry has seen significant growth over the past two decades. However, margins are under pressure due to several challenges: - Rising R&D costs at often challenging innovation rates - Increasing SG&A costs where not actively managed - General market access pressures across healthcare systems - Geopolitically driven energy and raw material price hikes - Inflation-induced wage increases Our #RolandBerger study provides a deep dive into the sector, analyzing over 160 of the largest publicly traded #Pharmaceutical and #LifeSciences companies. Discover how to navigate industry challenges and what sets winners in the industry apart: https://lnkd.in/diNp7seD Roland Berger Belgium happily supports local and international health players navigate their most critical challenges. Please feel free to contact our experts: Marco Bühren Matthias Bünte Morris Hosseini Thilo Kaltenbach Filip Conic Lennart Boesch Omer Saka Stephan Fath Grégoire Tondreau Astrid Böhlke #rolandberger #rbhealthbelgium #pharma #biotech #performance #innovation

Free webinar on the commercialization of pharmaceutical drugs in LMICs - sign up!

#GlobalScientificInstrumentMarket Poised for Major Growth: Powering Drug Discovery and Digital Pharma Evolution 💊🔬. As investments soar and online distribution channels expand, the landscape of drug development is being reshaped. Explore how tech and health are converging in this transformative market. Discover the full potential::https://shorturl.at/UhK7K #HealthcareInnovation #PharmaTrends #TechInHealthcare #MarketGrowth #DigitalTransformation #DrugDiscovery #OnlinePharmacy #GlobalHealth #MarketAnalysis #ConsumerTrends #MedicalResearch #PharmaSales #EmergingMarkets #InvestmentOpportunity #DataDrivenInsights #CompetitiveLandscape

How can biopharma companies be prepared for new policy changes in the unpredictable market with factors like the Inflation Reduction Act (IRA) at play? Biopharma companies should anticipate uncertainty and be prepared to react quickly to policy changes. Companies who want to get ahead should invest in tools that can aid in making decisions to respond appropriately to change.  Dana P Goldman, co-founder and scientific advisor for EntityRisk and dean of the University of Southern California USC Sol Price School of Public Policy and Jeffrey B. Kindler, former chairman and CEO at Pfizer and executive chairman at EntityRisk discuss the need for tools to build a comprehensive story around drug pricing in today’s market. Kindler asserts that having tools like EntityRisk help biopharma companies combat overreacting to policy changes and address new uncertainty in a “methodical way.” Listen to the full conversation between Dana, Jeff, and Neal Masia here to learn more: https://lnkd.in/dKN8ur8h #CMS #DrugPricing #BioPharma 

Timely and extremely important in the current macroenvironment.

A new change of pace is forcing #pharma companies to reconsider their offerings, and as a result, traditional models will fall behind. In the latest article in our series, Paula Bellostas Muguerza, Florian Leschinsky, and Keena Patel-Moran explore the question: How can pharma companies rethink their value propositions and resync their engagement models?: